{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:43:45Z","timestamp":1791413025568,"version":"4.3.3"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Prurigo nodularis (PN) is a chronic, intensely itchy skin condition linked to immune and nerve dysfunction, often affecting individuals with darker skin. It severely impacts quality of life. While traditional treatments are limited, nemolizumab shows promise. However, more diverse and long-term studies are needed to confirm its effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This systematic review followed PRISMA 2020 guidelines, analyzing studies on nemolizumab for PN. Data from multiple databases were assessed for efficacy, safety, and bias. Statistical analysis used Review Manager 5.4 with random-effects modeling and heterogeneity evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This meta-analysis included four randomized controlled trials (RCTs) involving 859 participants. Nemolizumab significantly improved Peak Pruritus Numerical Rating Scale (PP-NRS; \u22654 points) in weeks 4 and 16 [risk ratio (RR): 5.87 and 3.52], and PP-NRS &lt;2 (RR: 11.87 and 5.63). It also improved the Sleep Disturbance and Numerical Rationg Scale (SD-NRS) and Investigator\u2019s Global Assessment responses. Adverse events were slightly higher (RR: 1.13), though injection reactions, infections, headaches, and gastrointestinal events showed no significant differences. The risk of neurodermatitis was significantly lower with nemolizumab. Trial Sequential Analysis suggests that further large RCTs should be carried out to validate our results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This review confirms nemolizumab as an effective, well-tolerated treatment for PN, providing rapid relief from itching, skin lesions, and sleep issues. With a favorable safety profile, it marks a major advancement in managing this challenging, underserved condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004973","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:00:10Z","timestamp":1778079610000},"page":"3486-3495","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Targeting IL-31RA with nemolizumab in prurigo nodularis: a systematic review, GRADE-assessed meta-analysis, and trial sequential analysis of randomized controlled trials"],"prefix":"10.1097","volume":"88","author":[{"given":"Ali O.","family":"Aldamen","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Al Yarmouk University, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Second Health Cluster, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"College of Medicine, King Khalid University, Abha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab Mofareh","family":"Alanazi","sequence":"additional","affiliation":[{"name":"College of Medicine, Northern Border University, Arar, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamyaa Hamdan","family":"Almutairi","sequence":"additional","affiliation":[{"name":"College of Medicine, Vision Colleges, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla Sultan","family":"Alghatam","sequence":"additional","affiliation":[{"name":"College of Medicine, Arabian Gulf University, Manama, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alamari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, McGill University Health Center, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem","family":"Altamimi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-0251","authenticated-orcid":false,"given":"Rukesh","family":"Yadav","sequence":"additional","affiliation":[{"name":"College of Medicine, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Altamimi","sequence":"additional","affiliation":[{"name":"Pediatric Emergency and Medical Toxicology Department, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"R1-20260810","doi-asserted-by":"crossref","first-page":"1579\u201389","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"706\u201316","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"key":"R3-20260810","doi-asserted-by":"crossref","first-page":"200\u201308","DOI":"10.1093\/bjd\/ljae131","article-title":"Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II\/III clinical study in patients aged \u2265 13 years","volume":"191","author":"Yokozeki","year":"2024","journal-title":"Br J Dermatol"},{"key":"R4-20260810","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"798\u2013810","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: new insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br J Dermatol"},{"key":"R6-20260810","first-page":"1143\u201350","article-title":"Nemolizumab: first Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"R7-20260810","doi-asserted-by":"crossref","first-page":"249\u201356","DOI":"10.1016\/j.jid.2024.06.1276","article-title":"Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation","volume":"145","author":"Kwatra","year":"2025","journal-title":"J Invest Dermatol"},{"key":"R8-20260810","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich","year":"2023","journal-title":"Biomolecules"},{"key":"R9-20260810","first-page":"5\u20138","article-title":"Prurigo nodularis: review and emerging treatments","volume":"26","author":"Leis","year":"2021","journal-title":"Skin Therapy Lett"},{"key":"R10-20260810","doi-asserted-by":"crossref","first-page":"5\u201314","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"R11-20260810","first-page":"10\u201322","article-title":"Economic burden of atopic dermatitis","volume":"120","author":"Armstrong","year":"2018","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:01:53Z","timestamp":1786359713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004973","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2025-08-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}